<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31932031</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>Pre-symptomatic diagnosis in ALS.</ArticleTitle><Pagination><StartPage>166</StartPage><EndPage>169</EndPage><MedlinePgn>166-169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2019.07.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(19)30907-5</ELocationID><Abstract><AbstractText>Pathophysiology of amyotrophic lateral sclerosis (ALS) remains partially understood even though it is accepted worldwide that motor neuron death results from a pluri-factorial process with a variable role of genetic factors. Although not distinguishable from a clinical point of view, familial forms of ALS (fALS, 10% of cases) and sporadic forms (sALS, 90% of cases) can be described. Since the identification of superoxide dismutase 1 gene (SOD1) mutations, more than 30 genes have been linked to fALS. Among these genes, five (C9ORF72, SOD1, TARDBP, FUS, TBK1) seem predominant with mutation frequencies of 40%, 20%, 5%, &lt;5%, &lt;5% in fALS and 6%, 3%, and &lt;1% for the last three in sALS, respectively. The situation that classically leads to request genetic screening is the presence of a familial history of motor neuron disorders (MND) or fronto-temporal lobar dementia (FTLD). However, this dichotomy between fALS and sALS based on familial history can lead to mistakes since illegitimacy, ignorance of MND, FTD or psychiatric disorders within the family due to a familial censorship or lack of familial relationship, or a recessive autosomal inheritance could wrongly lead to failing to recognize a familial form. The significant development of genetic research and easier access to genetic tests in fALS increase the number of situations for which gene mutations are identified. The consequence is an increase in genetic requests from relatives of ALS patients who are eager to know their own genetic status and their own individual risk to develop ALS. Pre-symptomatic testing is thus becoming a daily issue in ALS Centers. This led us to propose a framework for such pre-symptomatic genetic testing for people at risk for developing ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre Constitutif SLA, CHU Bretonneau, Tours, France; UMR 1253,&#xa0;iBrain,&#xa0;Universit&#xe9;&#xa0;de Tours, Inserm, Tours, France. Electronic address: corcia@med.univ-tours.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbroso</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, Montpellier, France; Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHU N&#xee;mes, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cazeneuve</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit&#xe9; Fonctionnelle de Neurog&#xe9;n&#xe9;tique Mol&#xe9;culaire et Cellulaire, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique-H&#xf4;pitaux de Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouzat</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, Montpellier, France; Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHU N&#xee;mes, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Centre Consitutif SLA, Hopital Guy de Chauliac, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Motoneuron Disease: Pathophysiology and Therapy, INM, University Montpellier, Montpellier, France; Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHU N&#xee;mes, N&#xee;mes, France; Service de Biochimie et Biologie Mol&#xe9;culaire, CHRU Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>on Behalf the FILSLAN network</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003219" MajorTopicYN="N">Confidentiality</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030881" MajorTopicYN="N">Disclosure</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis</Keyword><Keyword MajorTopicYN="N">Counselling</Keyword><Keyword MajorTopicYN="N">Genetic</Keyword><Keyword MajorTopicYN="N">Presymptomatic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31932031</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2019.07.027</ArticleId><ArticleId IdType="pii">S0035-3787(19)30907-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>